---
title: "Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: References"
description: "Reference list for the formulary evidence report on Emiltatug ledadotin (Emi-Le, XMT-1660) in Adenoid cystic carcinoma with solid histology or high-grade transformation. 124 cited documents."
canonical: "https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references"
published: "2026-09-17T22:01:26-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: References

<a id="references"></a>

## 5 References

1. [ACCRF (2025)](https://accrf.org/new-b7-h4-adc/)
2. [ADC Review (2025)](https://www.adcreview.com/business-economics/pfizer-discontinues-development-of-felmetatug-vedotin/)
3. [Airoldi et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11169936/)
4. [Amit et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4988229/)
5. [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)
6. [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)
7. [Bölek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12481798/)
8. [Boyle et al. (2020)](https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e13600)
9. [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)
10. [ClinicalTrials.gov NCT03691207](https://clinicaltrials.gov/study/NCT03691207)
11. [ClinicalTrials.gov NCT04883671](https://clinicaltrials.gov/study/NCT04883671)
12. [ClinicalTrials.gov NCT05123482](https://clinicaltrials.gov/study/NCT05123482)
13. [ClinicalTrials.gov NCT05194072](https://clinicaltrials.gov/study/NCT05194072)
14. [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)
15. [ClinicalTrials.gov NCT07162480](https://clinicaltrials.gov/study/NCT07162480)
16. [CMS (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)
17. [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)
18. [CURE (2026)](https://www.curetoday.com/view/experimental-treatment-shrinks-tumors-in-rare-salivary-gland-cancer)
19. [Day One Biopharmaceuticals (2025)](https://www.sec.gov/Archives/edgar/data/1845337/000110465925110812/tm2531072d1_ex99-1.htm)
20. [Day One Biopharmaceuticals acquisition completion announcement (2026)](https://www.globenewswire.com/news-release/2026/01/06/3213738/0/en/Day-One-Completes-Acquisition-of-Mersana-Therapeutics.html)
21. [Day One Biopharmaceuticals acquisition presentation (2025)](https://www.sec.gov/Archives/edgar/data/1845337/000110465925110812/tm2531072d1_ex99-2.htm)
22. [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)
23. [Day One Biopharmaceuticals Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526171997/d27888d8k.htm)
24. [Day One Biopharmaceuticals J.P. Morgan Healthcare Conference presentation (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526009834/d57290dex992.htm)
25. [Day One Biopharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066926/dawn-ex99_3.htm)
26. [Day One Biopharmaceuticals Schedule 14D-9 (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526125045/d55037dsc14d9.htm)
27. [de Sousa and Ferrarotto (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584030/)
28. [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)
29. [DelveInsight (2026)](https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market)
30. [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/)
31. [FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018)](https://www.fda.gov/media/71195/download)
32. [Ferrand et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38061943/)
33. [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)
34. [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)
35. [Ferrarotto et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414730/)
36. [Ferrarotto et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38118249/)
37. [Ferrarotto et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6009)
38. [Galot and Machiels (2026)](https://pubmed.ncbi.nlm.nih.gov/41222550/)
39. [Geiger et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33900808/)
40. [Girelli et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28341276/)
41. [GSK BEHOLD-1 data announcement (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynaecological-cancers/)
42. [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)
43. [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)
44. [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)
45. [Hanna et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32283496/)
46. [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)
47. [Hanna et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501326/)
48. [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)
49. [Hanna et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12947079/)
50. [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)
51. [Ho et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3708595/)
52. [Ho et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5035791/)
53. [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)
54. [Ho et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3089)
55. [Hoff et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11140580/)
56. [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/)
57. [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/)
58. [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/)
59. [IMARC Group (2026)](https://www.imarcgroup.com/adenoid-cystic-carcinoma-market)
60. [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)
61. [Jacobson et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3503554/)
62. [Jensen and Debus (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6836331/)
63. [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)
64. [Kang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41432961/)
65. [Keam et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25903089/)
66. [Kim et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11491249/)
67. [Kinneer et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36355054/)
68. [Laurie et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21147032/)
69. [Locati et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27821319/)
70. [Locati et al. (2019)](https://doi.org/10.1002/hed.25891)
71. [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)
72. [Lombardi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35158286/)
73. [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)
74. [Meric-Bernstam et al. (2024)](https://www.annalsofoncology.org/article/S0923-7534(24)02192-6/fulltext)
75. [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)
76. [Mersana Therapeutics ASCO 2025 presentation (2025)](https://ir.mersana.com/static-files/9773978b-21fc-43cc-8529-2acba33cf29c)
77. [Mersana Therapeutics Day One merger announcement (2025)](https://www.globenewswire.com/news-release/2025/11/13/3187105/0/en/Day-One-Biopharmaceuticals-to-Acquire-Mersana-Therapeutics.html)
78. [Mersana Therapeutics Fast Track announcement (2025)](https://www.biospace.com/press-releases/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadotin-xmt-1660)
79. [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)
80. [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)
81. [Mersana Therapeutics Form 8-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925110764/tm2531148d1_8k.htm)
82. [Mersana Therapeutics initial clinical data announcement (2025)](https://www.globenewswire.com/news-release/2025/01/10/3007493/0/en/Mersana-Therapeutics-Announces-Positive-Initial-Clinical-Data-from-Phase-1-Clinical-Trial-of-Emiltatug-Ledadotin-XMT-1660-Initiation-of-Expansion-in-Triple-Negative-Breast-Cancer.html)
83. [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)
84. [Mersana Therapeutics Schedule 14D-9 (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925118903/tm2532730d1_sc14d9.htm)
85. [Michaeli and Michaeli (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10791980/)
86. [Mitani et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5862426/)
87. [Morita et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7935776/)
88. [NCCN Guidelines Head and Neck Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437)
89. [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)
90. [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)
91. [OncLive Hanna interview (2026)](https://www.onclive.com/view/dr-hanna-on-the-safety-and-efficacy-of-emi-le-in-aggressive-acc)
92. [Pal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12507167/)
93. [Persson et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2773970/)
94. [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)
95. [Rahouma et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11476411/)
96. [Rai et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-3/review-of-us-cost-effectiveness-evaluations-for-antibody-drug-conjugates-adcs-in-oncology)
97. [Ran et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893857/)
98. [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/)
99. [Research and Markets (2026)](https://www.researchandmarkets.com/reports/6265219/adenoid-cystic-carcinoma-market-share)
100. [Sahara et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493384/)
101. [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/)
102. [Seethala et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21204718/)
103. [Servier acquisition completion announcement (2026)](https://servier.com/en/newsroom/servier-completes-the-acquisition-of-day-one-biopharmaceuticals/)
104. [Servier and Day One Biopharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526095174/d108979dex991.htm)
105. [Servier ASCO 2026 presentations announcement (2026)](https://servier.mediaroom.com/2026-05-21-Servier-Presentations-at-ASCO-2026-Spotlight-Expanding-Rare-Oncology-Portfolio)
106. [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)
107. [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)
108. [Servier EMBLEM-1 first patients dosed announcement (2026)](https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma)
109. [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)
110. [Siqueira et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12419983/)
111. [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)
112. [Skálová et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018948/)
113. [Szanto et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/6088017/)
114. [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/)
115. [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)
116. [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)
117. [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)
118. [van Weert et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25456010/)
119. [van Weert et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27775851/)
120. [Vos et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293616/)
121. [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320353/)
122. [Zhang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35822446/)
123. [Zhu et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8111556/)
124. [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

## Related pages
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Terms and abbreviations](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations.md)
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Product information and disease description](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Clinical evidence](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Economic information and modeling report](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: prevalence by geography](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses.md)
